[144] ROCKWELL MEDICAL, INC. SEC Filing
Rockwell Medical, Inc. (RMTI) filing a Form 144 reports a proposed sale of 2,868 common shares through Raymond James & Associates on 10/01/2025 on NASDAQ with an aggregate market value of 3,321.00. The filing shows the securities were acquired by the seller through RSU vesting on 03/15/2024 (10,010 shares) and 03/14/2025 (8,666 shares). The filer sold 2,868 shares on 07/01/2025 for gross proceeds of 2,271.00. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.
Rockwell Medical, Inc. (RMTI) ha presentato un modulo Form 144 che riporta la vendita proposta di 2.868 azioni ordinarie tramite Raymond James & Associates in data 10/01/2025 sul NASDAQ, con un valore di mercato aggregato di 3.321,00. La dichiarazione mostra che i titoli sono stati acquisiti dal venditore tramite vesting RSU il 15/03/2024 (10.010 azioni) e 14/03/2025 (8.666 azioni). Il dichiarante ha venduto 2.868 azioni 01/07/2025 per ricavo lordo di 2.271,00. L'avviso include l'attestazione standard che il venditore non possiede informazioni materiali sfavorevoli non divulgate.
Rockwell Medical, Inc. (RMTI) presentó un Formulario 144 que informa la venta propuesta de 2.868 acciones ordinarias a través de Raymond James & Associates el 10/01/2025 en NASDAQ, con un valor de mercado agregado de 3.321,00. La declaración muestra que los valores fueron adquiridos por el vendedor mediante vesting de RSU el 15/03/2024 (10.010 acciones) y el 14/03/2025 (8.666 acciones). El declarante vendió 2.868 acciones el 01/07/2025 por ingresos brutos de 2.271,00. El aviso incluye la certificación estándar de que el vendedor no posee información material adversa no revelada.
Rockwell Medical, Inc. (RMTI)가 Form 144를 제출하여 2,868주를 Raymond James & Associates을 통해 NASDAQ에서 2025/10/01에 매각하겠다는 제안을 보고하고 있으며 총 시장가치는 3,321.00입니다. 서류에 따르면 피매도자는 RSU vesting으로 2024/03/15에 10,010주와 2025/03/14에 8,666주를 취득했습니다. 신고자는 2025/07/01에 2,868주를 매각했고 총수익은 2,271.00입니다. 공지에는 매도인이 미공개된 중대한 악정보가 없다는 표준 확인이 포함되어 있습니다.
Rockwell Medical, Inc. (RMTI) dépose un Formulaire 144 qui rapporte la vente proposée de 2 868 actions ordinaires par l'intermédiaire de Raymond James & Associates le 01/10/2025 sur le NASDAQ, pour une valeur de marché totale de 3 321,00. Le dossier indique que les titres ont été acquis par le vendeur via un vesting RSU le 15/03/2024 (10 010 actions) et le 14/03/2025 (8 666 actions). Le déclarant a vendu 2 868 actions le 01/07/2025 pour un produit brut de 2 271,00. L'avis comprend l'attestation standard selon laquelle le vendeur ne détient aucune information matérielle défavorable non divulguée.
Rockwell Medical, Inc. (RMTI) reicht ein Formular 144 ein, das einen vorgeschlagenen Verkauf von 2.868 Stammaktien über Raymond James & Associates am 01.10.2025 an der NASDAQ mit einem aggregierten Marktwert von 3.321,00 meldet. Die Unterlagen zeigen, dass die Wertpapiere vom Verkäufer durch RSU-Vesting am 15.03.2024 (10.010 Aktien) und am 14.03.2025 (8.666 Aktien) erworben wurden. Der Einreicher hat am 01.07.2025 2.868 Aktien für einen Bruttoerlös von 2.271,00 verkauft. Die Mitteilung enthält die Standardbestätigung, dass der Verkäufer keine unausgewiesenen wesentlichen nachteiligen Informationen besitzt.
تقدّم Rockwell Medical, Inc. (RMTI) نموذج 144 الذي يبلغ عن بيع مقترح لـ 2,868 سهمًا عاديًا عبر Raymond James & Associates في 01/10/2025 على ناسداك، بقيمة سوقية إجمالية قدرها 3,321.00. تبين الوثيقة أن الأوراق المالية قد تم الحصول عليها من قبل البائع من خلال vesting RSU في 15/03/2024 (عشر آلاف و10 أسهم) و14/03/2025 (8,666 أسهم). باع المقيّد 2,868 سهمًا في 01/07/2025 مقابل عوائد إجمالية قدرها 2,271.00. يتضمن الإشعار التصديق القياسي بأن البائع لا يمتلك معلومات مادية سلبية غير مكشوفة.
Rockwell Medical, Inc. (RMTI) 提交了一份 Form 144,报告通过 Raymond James & Associates 于 2025/10/01 在 NASDAQ 上拟议出售 2,868 股普通股,总代价为 3,321.00。该申报显示,股权通过 RSU 授予于 2024/03/15(10,010 股)及 2025/03/14(8,666 股)由卖方取得。申报人于 2025/07/01 以毛收益 2,271.00 出售了 2,868 股。通知包含标准声明,卖方不存在未披露的重大不利信息。
- Disclosure of RSU origin: the filing clearly states the shares were acquired via RSU vesting on 03/15/2024 and 03/14/2025.
- Timely regulatory notice: proposed sale and prior sale are disclosed consistent with Rule 144 requirements.
- Small relative size: 2,868 shares is immaterial compared with 34,430,352 shares outstanding.
- Insider sale: the person for whose account the sale is reported has sold and plans to sell shares, which could be perceived negatively by some investors.
- Limited detail: the filing contains no explanation of the reason for the sale beyond RSU origin and standard attestations.
Insights
TL;DR: Insider plans a small sale of vested RSUs; transaction size is immaterial versus total shares outstanding.
The filing indicates a planned sale of 2,868 common shares derived from RSU vesting, executed via a broker on a specified date. Compared with the reported 34,430,352 shares outstanding, this represents a de minimis portion of the public float and is unlikely to materially affect valuation or market liquidity. The prior sale on 07/01/2025 for 2,271.00 shows active disposition of vested awards. No financial performance metrics or additional corporate actions are disclosed.
TL;DR: This is a routine insider disclosure showing RSU-derived sales and the customary attestation about material nonpublic information.
The document records that the securities originated from RSU vesting dates in 2024 and 2025 and that sales are being routed through Raymond James & Associates. The signer affirms compliance with disclosure requirements and the absence of undisclosed material adverse information. The filing contains required seller representations and a past sale record, aligning with Rule 144 procedural expectations. No governance actions or policy changes are reported.
Rockwell Medical, Inc. (RMTI) ha presentato un modulo Form 144 che riporta la vendita proposta di 2.868 azioni ordinarie tramite Raymond James & Associates in data 10/01/2025 sul NASDAQ, con un valore di mercato aggregato di 3.321,00. La dichiarazione mostra che i titoli sono stati acquisiti dal venditore tramite vesting RSU il 15/03/2024 (10.010 azioni) e 14/03/2025 (8.666 azioni). Il dichiarante ha venduto 2.868 azioni 01/07/2025 per ricavo lordo di 2.271,00. L'avviso include l'attestazione standard che il venditore non possiede informazioni materiali sfavorevoli non divulgate.
Rockwell Medical, Inc. (RMTI) presentó un Formulario 144 que informa la venta propuesta de 2.868 acciones ordinarias a través de Raymond James & Associates el 10/01/2025 en NASDAQ, con un valor de mercado agregado de 3.321,00. La declaración muestra que los valores fueron adquiridos por el vendedor mediante vesting de RSU el 15/03/2024 (10.010 acciones) y el 14/03/2025 (8.666 acciones). El declarante vendió 2.868 acciones el 01/07/2025 por ingresos brutos de 2.271,00. El aviso incluye la certificación estándar de que el vendedor no posee información material adversa no revelada.
Rockwell Medical, Inc. (RMTI)가 Form 144를 제출하여 2,868주를 Raymond James & Associates을 통해 NASDAQ에서 2025/10/01에 매각하겠다는 제안을 보고하고 있으며 총 시장가치는 3,321.00입니다. 서류에 따르면 피매도자는 RSU vesting으로 2024/03/15에 10,010주와 2025/03/14에 8,666주를 취득했습니다. 신고자는 2025/07/01에 2,868주를 매각했고 총수익은 2,271.00입니다. 공지에는 매도인이 미공개된 중대한 악정보가 없다는 표준 확인이 포함되어 있습니다.
Rockwell Medical, Inc. (RMTI) dépose un Formulaire 144 qui rapporte la vente proposée de 2 868 actions ordinaires par l'intermédiaire de Raymond James & Associates le 01/10/2025 sur le NASDAQ, pour une valeur de marché totale de 3 321,00. Le dossier indique que les titres ont été acquis par le vendeur via un vesting RSU le 15/03/2024 (10 010 actions) et le 14/03/2025 (8 666 actions). Le déclarant a vendu 2 868 actions le 01/07/2025 pour un produit brut de 2 271,00. L'avis comprend l'attestation standard selon laquelle le vendeur ne détient aucune information matérielle défavorable non divulguée.
Rockwell Medical, Inc. (RMTI) reicht ein Formular 144 ein, das einen vorgeschlagenen Verkauf von 2.868 Stammaktien über Raymond James & Associates am 01.10.2025 an der NASDAQ mit einem aggregierten Marktwert von 3.321,00 meldet. Die Unterlagen zeigen, dass die Wertpapiere vom Verkäufer durch RSU-Vesting am 15.03.2024 (10.010 Aktien) und am 14.03.2025 (8.666 Aktien) erworben wurden. Der Einreicher hat am 01.07.2025 2.868 Aktien für einen Bruttoerlös von 2.271,00 verkauft. Die Mitteilung enthält die Standardbestätigung, dass der Verkäufer keine unausgewiesenen wesentlichen nachteiligen Informationen besitzt.